新辅助免疫化疗后扩大袖状肺叶切除术治疗中心型非小细胞肺癌
该多中心回顾性研究纳入2019至2023年94例接受新辅助免疫化疗的中心型NSCLC患者,其中18例行扩大袖状肺叶切除术(ESL)、42例行标准袖状肺叶切除术(SSL)、34例行全肺切除术。
要点
- 新辅助免疫化疗后行ESL安全可行,可作为全肺切除术的替代选择。
核心结论
- 新辅助免疫化疗后行ESL对经选择的中心型NSCLC患者是可行且安全的选择,可避免全肺切除,尤其当SSL不足以实现R0切除时。
研究设计与样本
- 多中心回顾性研究,纳入2019至2023年2个高容量中心的94例接受新辅助免疫化疗的中心型NSCLC患者,按术式分为ESL组18例、SSL组42例、全肺切除组34例。
主要发现
- ESL组、SSL组和全肺切除组分别有18例、42例和34例患者。
- 术后并发症主要见于全肺切除组(32.4%)。
- Kaplan-Meier曲线显示ESL与SSL之间无差异。
临床怎么用
- 对经选择的中心型NSCLC患者,新辅助免疫化疗后可行ESL以保留更多肺实质并避免全肺切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended sleeve lobectomy (ESL) is proposed as an effective alternative to pneumonectomy for patients who are not amenable to standard sleeve lobectomy (SSL), which is designed to preserve more lung parenchyma and improve postoperative quality of life. However, the safety and feasibility of ESL after neoadjuvant immunochemotherapy remain unclear. METHODS: Between 2019 and 2023, 94 patients with central non-small cell lung cancer (NSCLC) received neoadjuvant immunochemotherapy, followed by pneumonectomy, ESL, or SSL, in 2 high-volume centers. Perioperative, surgical, pathologic, and survival outcomes were meticulously analyzed to evaluate the impact of neoadjuvant immunochemotherapy. RESULTS: ESL, SSL, and pneumonectomy were performed in 18, 42, and 34 patients, respectively. Patients who underwent ESL had a poorer predicted postoperative forced expiratory volume in 1 second percentage than those who underwent pneumonectomy (P < .01), if pneumonectomy was to be conducted. R0 resection was confirmed in 90 patients (95.7%), including 17 (94.4%) in ESL, 41 (97.6%) in SSL, and 32 (94.1%) in pneumonectomy (P = .72). Postoperative complications were predominantly observed in patients who underwent pneumonectomy (32.4%). Kaplan-Meier curves showed no difference between ESL and SSL. Compared with pneumonectomy, ESL had a longer event-free survival (P = .04). CONCLUSIONS: ESL after neoadjuvant immunochemotherapy is a viable and safe option for selected patients with centrally located NSCLC to avoid pneumonectomy, especially when SSL is insufficient for R0 resection.
引用
- Chen J, Zhao ZR, Deng H, et al. Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer. Ann Thorac Surg. 2025. PMID: 40216350. doi:10.1016/j.athoracsur.2025.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。